Ruben Magni

Ruben Magni

Auto-generated profile, based on publicly available information

Ruben Magni

School of Systems Biology, George Mason University, Fairfax, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2017 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
LPLuisa Paris
Luisa Paris
RMRuben Magni
Ruben Magni
FZFatima Zaidi
Fatima Zaidi
RARobyn Araujo
Robyn Araujo
NSNeal Saini
Neal Saini
LLLance Liotta
Lance Liotta
The Mycobacterium tuberculosis –specific antigen lipoarabinomannan measured in the urine of HIV-negative, pulmonary TB-infected patients correlates with disease severity.

2 March 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
HSHannah E. Steinberg
Hannah E. Steinberg
NBNatalie Bowman
Natalie Bowman
ADAndrea Jackeline Diestra
Andrea Jackeline Diestra
CFCusi Ferradas
Cusi Ferradas
PRPaul Russo
Paul Russo
TBthe Toxoplasmosis working group in Peru and Bolivia
the Toxoplasmosis working group in Peru and Bolivia
Background: Diagnosis of toxoplasmic encephalitis (TE) is challenging under the best clinical circumstances. The poor clinical sensitivity of quantitative polymerase chain reaction (qPCR) forToxoplasmain blood and CSF and the limited availability of molecular diagnostics and imaging technology leaves clinicians in resource-limited settings with few options other than empiric treatment.Methology/principle findings: Here we describe proof of concept for a novel urine diagnostics for TE using Poly-N-Isopropylacrylamide nanoparticles dyed with Reactive Blue-221 to concentrate antigens, substantially increasing the limit of detection. After nanoparticle-concentration, a standard western blotting technique with a monoclonal antibody was used for antigen detection. Limit of detection was 7.8pg/ml and 31.3pg/ml ofT.gondiiantigens GRA1 and SAG1, respectively. To characterize this diagnostic approach, 164 hospitalized HIV-infected patients with neurological symptoms compatible with TE were tested for 1)T.gondiiserology (121/147, positive samples/total samples tested), 2) qPCR in cerebrospinal fluid (11/41), 3) qPCR in blood (10/112), and 4) urinary GRA1 (30/164) and SAG1 (12/164). GRA1 appears to be superior to SAG1 for detection of TE antigens in urine. Fifty-one HIV-infected,T.gondiiseropositive but asymptomatic persons all tested negative by nanoparticle western blot and blood qPCR, suggesting the test has good specificity for TE for both GRA1 and SAG1. In a subgroup of 44 patients, urine samples were assayed with mass spectrometry parallel-reaction-monitoring (PRM) for the presence ofT.gondiiantigens. PRM identified antigens in 8 samples, 6 of which were concordant with the urine diagnostic.Conclusion/significances: Our results demonstrate nanoparticle technology’s potential for a noninvasive diagnostic test for TE. Moving forward, GRA1 is a promising target for antigen based diagnostics for TE.

24 July 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MCMeenal Chand
Meenal Chand
PVPratap Vydyam
Pratap Vydyam
APAnasuya C Pal
Anasuya C Pal
JTJose Thekkiniath
Jose Thekkiniath
DDDounia Darif
Dounia Darif
CMChoukri Ben Mamoun
Choukri Ben Mamoun
Human babesiosis is an emerging and potentially fatal tick-borne disease caused by intraerythrocytic parasites of the Babesia genus. Among these, Babesia duncani is particularly notable for causing severe and life-threatening illness in humans. Accurate diagnosis and effective disease management hinge on the detection of active B. duncani infections. While molecular assays are available to detect the parasite in blood, a reliable method for identifying biomarkers of active infection remains elusive. We developed the first B. duncani antigen capture assays, targeting two immunodominant antigens, BdV234 and BdV38. These assays were validated using established in vitro and in vivo B. duncani infection models, and following drug treatment. The assays demonstrated no cross-reactivity with other species such as B. microti, B. divergens, Babesia MO1, or Plasmodium falciparum, and can detect as few as 115 infected erythrocytes/µl of blood. Screening of 1731 blood samples from various biorepositories, including samples previously identified as Lyme and/or B. microti-positive, as well as new specimens from wild mice, revealed no evidence of B. duncani infection or cross-reactivity. These assays hold significant promise for various applications, including point-of-care testing for the early detection of B. duncani in patients, field tests for screening reservoir hosts, and high-throughput screening of blood samples intended for transfusion.